asp8374
mAbexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 8, 2017 (NCT03260322)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
TIGIT antagonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04826393 | Phase 1 | Dec 31, 2021 | Astellas, Harvard University, ImaginAb, Inc., Regeneron |
| NCT03945253 | Phase 1 | Jun 30, 2019 | Astellas |
| NCT03260322 | Phase 1 | Sep 8, 2017 | Astellas, Potenza Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 3 | 2 | 1 | 2017 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| ImaginAb, Inc. | For profit | 1 | 0 | 1 | 2021 |
| Potenza Therapeutics | For profit | 1 | 0 | 1 | 2017 |
| Regeneron | For profit | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1